

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences for alternative medicines.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with local clinical experts. It offers a choice of medicines for healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines in it and also helps make sure that standards of care are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland, it looks at:
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence Multiple Technology Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board consider whether to add new medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

What happens if a particular medicine is not routinely available in NHSGG&C?

- If a medicine is not routinely available and included in the GGC Formulary and there are no suitable alternatives on the formulary, a healthcare professional can request to prescribe a medicine that is not on the formulary if they think you will benefit from using it. NHSGG&C and all health boards have procedures in place to consider requests when a healthcare professional feels a medicine that is not on the formulary would be right for a particular patient.

The table below lists NHS Greater Glasgow and Clyde's decisions on new medicines.

If you need more information on medicines decisions in NHS Greater Glasgow and Clyde, please email ggc.medicines@ggc.scot.nhs.uk

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

Alectinib capsules Alecensa® 2012	As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). https://www.scottishmedicines.org.uk/media/3645/alectinib-hydrochloride-alecensa-final-july-2018-for-website.pdf	Routinely available in line with local or regional guidance	13/08/2018
Atezolizumab infusion Tecentriq® 1336/18	As monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumour mutations should also have received targeted therapy before receiving atezolizumab. https://www.scottishmedicines.org.uk/media/3554/atezolizumab-tecentriq-final-june-2018-for-website.pdf	Routinely available in line with local or regional guidance	13/08/2018
Bosutinib tablets Bosulif® 2109	Treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia. https://www.scottishmedicines.org.uk/medicines-advice/bosutinib-bosulif-non-submission-smc2109/	Not routinely available as not recommended for use in NHSScotland	13/08/2018
Brentuximab infusion Adcetris® SMC2098	Treatment of adult patients with CD30+ cutaneous T-cell lymphoma after at least one prior systemic therapy. https://www.scottishmedicines.org.uk/medicines-advice/brentuximab-vedotin-adcetris-non-submission-smc2098/	Not routinely available as not recommended for use in NHSScotland	13/08/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Conestat Alfa injection Ruconest® 745/11	For treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency https://www.scottishmedicines.org.uk/media/3647/conestat-alfa-ruconest-final-20180808-for-website.pdf	Routinely available in line with national guidance	13/08/2018
Denosumab injection Xgeva® 2110	Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with haematological malignancies involving bone. https://www.scottishmedicines.org.uk/medicines-advice/denosumab-xgeva-non-submission-smc2110/	Not routinely available as not recommended for use in NHSScotland	13/08/2018
Glycerol Phenylbutyrate oral liquid Ravicti® 1342/18	For use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. https://www.scottishmedicines.org.uk/media/3649/glycerol-phenylbutyrate-ravict-final-july-2018-for-website.pdf	Routinely available in line with national guidance	13/08/2018
Ixazomib capsules Ninlaro® SMC2099	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. https://www.scottishmedicines.org.uk/medicines-advice/ixazomib-ninlaro-non-submission-smc2099/	Not routinely available as not recommended for use in NHSScotland	13/08/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Lutetium oxodotreotide infusion Lutathera® 1337/18 https://www.scottishmedicines.org.uk/media/3557/lutetium-177lu-oxodotreotide-lutathera-final-june-2018-for-website.pdf	Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.	Routinely available in line with local or regional guidance	13/08/2018
Midostaurin capsules Rydapt® SMC2100 https://www.scottishmedicines.org.uk/medicines-advice/midostaurin-rydapt-non-submission-smc2100/	Monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia.	Not routinely available as not recommended for use in NHSScotland	13/08/2018
Niraparib tosylate monohydrate capsules Zejula® 1341/18 https://www.scottishmedicines.org.uk/media/3650/niraparib-tosylate-monohydrate-zejula-final-july-2018-amended-240718-for-website.pdf	As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy	Routinely available in line with local or regional guidance	13/08/2018
Ocrelizumab infusion Ocrevus® 1344/18 https://www.scottishmedicines.org.uk/media/3603/ocrelizumab-ocrevus-final-june-2018-for-website.pdf	Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Not routinely available as not recommended for use in NHSScotland	13/08/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Patiromer powder for oral suspension Veltassa® 2084 https://www.scottishmedicines.org.uk/media/3651/patiromer-sorbitex-calcium-veltassa-final-july-2018-for-website.pdf	The treatment of hyperkalaemia in adults	Not routinely available as not recommended for use in NHSScotland	13/08/2018
Progesterone injection Lubion® SMC2017 https://www.scottishmedicines.org.uk/media/3560/progesterone-lubion-abbreviated-final-june-2018-for-website.pdf	In adults for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations.	Routinely available in line with national guidance	13/08/2018
Raltegravir oral suspension Isentress® SMC2101 https://www.scottishmedicines.org.uk/medicines-advice/raltegravir-isentress-non-submission-smc2101/	In combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.	Not routinely available as not recommended for use in NHSScotland	13/08/2018
Sapropterin Dihydrochloride soluble tablets Kuvan® 558/09 https://www.scottishmedicines.org.uk/media/3652/sapropterin-kuvan-final-july-2018-for-website.pdf	The treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.	Not routinely available as not recommended for use in NHSScotland	13/08/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Tivozanib capsules Fotivda® 1335/18	First-line treatment of adult patients with advanced renal cell carcinoma and for adult patients who are vascular endothelial growth factor receptor and mammalian target of rapamycin pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced renal cell carcinoma (RCC). https://www.scottishmedicines.org.uk/media/3562/tivozanib-fotivda-final-june-2018-for-website.pdf	Routinely available in line with local or regional guidance	13/08/2018